Patents Assigned to Max-Delbrueck Centrum fuer Molekulare Medizin
-
Publication number: 20240150718Abstract: It is provided a method for gene repair in primary human muscle stem cells (satellite cells) in vitro comprising the following steps: providing a sample of an isolated muscle-fiber containing tissue sample collected from at least one patient with a monogenic muscle disease, wherein the monogenic muscle disease is caused by at least one mutation in at least one gene encoding for at least one muscle protein; isolating and cultivating primary stem cells from said muscle-fiber containing tissue sample, and correcting the at least one mutation in the at least one gene encoding for at least one muscle protein in the cultivated primary stem cells by targeted modification of the at least one mutation by gene editing using CRISPR/Cas-based tools.Type: ApplicationFiled: January 31, 2022Publication date: May 9, 2024Applicants: CHARITÉ - UNIVERSITAETSMEDIZIN BERLIN, MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Simone SPULER, Helena ESCOBAR, Christian STADELMANN
-
Publication number: 20240087677Abstract: A method for analysis of omics data related to samples derived from a human, animal or disease model is disclosed. The method comprises the steps of: a) Determining a plurality of latent spaces by inputting the omics data into a plurality of omics neural networks in parallel and achieving a plurality of latent spaces each comprising a set of latent factors by performing the calculations of the plurality of omics neural networks in a data processing unit, wherein the output of the omics neural networks each provides a respective latent space; b) Consolidating the plurality of latent spaces into one reproducible latent space, wherein the step of consolidating is processed by a data processing unit; wherein the consolidated latent factors represent characteristics of the samples to be analyzed.Type: ApplicationFiled: January 19, 2022Publication date: March 14, 2024Applicant: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventors: Vedran FRANKE, Bora UYAR, Jonathan RONEN, Altuna AKALIN
-
Patent number: 11891635Abstract: A method for modifying double stranded DNA (dsDNA) employing an RNA guided DNA endonuclease to generate two double strand breaks in the dsDNA molecule to be modified, and replacement of the sequence positioned between the double strand breaks with a substitute DNA sequence using the non-homologous end joining (NHEJ) pathway, and corresponding kits and compositions for modifying double stranded DNA molecules.Type: GrantFiled: December 21, 2018Date of Patent: February 6, 2024Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventors: Ralf Kühn, Eric Danner
-
Patent number: 11820829Abstract: A nucleic acid molecule encoding an antibody or antibody fragment, wherein the antibody or antibody fragment binds an epitope of the extracellular domain of CD269 (BCMA), a host cell comprising the nucleic acid molecule and a composition comprising the host cell.Type: GrantFiled: October 23, 2020Date of Patent: November 21, 2023Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventors: Felix Oden, Stephen Marino, Oliver Daumke
-
Publication number: 20230287343Abstract: A method for generating a three-dimensional neuromuscular organoid in vitro includes providing a first cell culture that includes disease-specific neuromesodermal progenitor cells, 30% to 90% of which co-express BRACHYURY/SOX2 and 10% to 70% of which co-express TBX6. The disease-specific neuromesodermal progenitor cells are cultivated in a first differentiation medium chosen from the group consisting of i) a non-supplemented serum-free cell culture medium and ii) a serum-free cell culture medium supplemented with at least one of a ROCK inhibitor, an activator of a growth factor signaling pathway, and an activator of an insulin signaling pathway. The first differentiation medium is replaced by a second differentiation medium within 1 to 3 days after cultivation start. The second differentiation medium is replaced by a non-supplemented serum-free cell culture medium within another 1 to 3 days. A three-dimensional neuromuscular organoid is obtained from the non-supplemented serum-free cell culture medium.Type: ApplicationFiled: July 12, 2021Publication date: September 14, 2023Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventor: Asimina GKOUTI
-
Patent number: 11667722Abstract: A composition comprising a cell or a population thereof, wherein the cell comprises a polynucleotide encoding an antibody or a fragment thereof that binds CD269 (BCMA), wherein the binding to CD269 (BCMA) disrupts the interaction between CD269 and its native ligands (BAFF and APRIL). Also disclosed is treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.Type: GrantFiled: July 8, 2020Date of Patent: June 6, 2023Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
-
Patent number: 11661588Abstract: The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transposon, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.Type: GrantFiled: November 3, 2017Date of Patent: May 30, 2023Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Zsuzsanna Izsvak, Zoltan Ivics, Lajos Mates, Namitha Manoj, Carmen-Anisia Judis, Andrea Katzer
-
Patent number: 11643468Abstract: An isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a human CXC chemokine receptor type 5 (CXCR5) protein. Also disclosed is a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CXCR5, preferably pathogenic mature B cells and/or memory B cells, and/or pathogenic T cells and/or T follicular helper cells, in particular mature B cell non-Hodgkin's lymphoma (B-NHL), T cell non-Hodgkin's lymphoma, or autoantibody-dependent autoimmune disease, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis.Type: GrantFiled: August 23, 2018Date of Patent: May 9, 2023Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Hemlholtz-GemeinschaftInventors: Uta Höpken, Armin Rehm, Julia Bluhm, Wolfgang Uckert
-
Patent number: 11447536Abstract: The present invention pertains to novel high avidity antigen recognizing constructs, such as antibodies or T cell receptors, which specifically bind to the melanoma associated antigen (MAGE) A1. The constructs of the invention are particularly useful for the diagnosis, prevention or therapy of tumorous diseases which are characterized by the specific expression of the MAGE-A1 antigen. Furthermore provided are nucleic acids, vectors and host cells—such as CD4 or CD8 positive T cells—which encode, comprise or present the antigen recognizing constructs of the invention. The invention thus provides new approaches for immune therapy, specifically adoptive T cell therapy, for treating cancer.Type: GrantFiled: July 10, 2019Date of Patent: September 20, 2022Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCHInventors: Thomas Blankenstein, Matthias Obenaus, Catarina Leitâo
-
Patent number: 11401316Abstract: The present invention pertains to novel high avidity antigen recognizing constructs against Human Papilloma Virus antigens. The invention provides novel T cell receptor (TCR) based molecules which are selective and specific for HPV 16/18 proteins E5, E6 and E7. The TCR of the invention, and HPV antigen-binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of HPV infection, as well as for the diagnosis, treatment and prevention of HPV infection mediated secondary diseases as HPV infection caused cancers, such as cervical, nasopharyngeal or head and neck cancer. Further provided are nucleic acids encoding the proteins of the invention, and recombinant cells expressing the same.Type: GrantFiled: October 13, 2016Date of Patent: August 2, 2022Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventors: Thomas Blankenstein, Gerald Willimsky
-
Patent number: 11396664Abstract: The invention relates to a system and method for introducing DNA into cells. In particular, the invention relates to a method for introducing single or multiple copies of a DNA sequence or gene of interest into a cell comprising providing: a) a “copy and paste” transposase; and b) a construct comprising a DNA sequence or gene of interest flanked by a “copy and paste” transposon terminal sequence, such as an LTS or RTS. A novel “copy and paste” transposon of the Helitron family is described along with systems for using the corresponding transposase in methods for introducing DNA into cells, for example, to generate cell lines for use in protein production, cell and gene therapy or as reference standards.Type: GrantFiled: February 10, 2017Date of Patent: July 26, 2022Assignees: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT, GENETIC INFORMATION RESEARCH INSTITUTEInventors: Tilmann Buerckstuemmer, Vladimir Vyacheslavovich Kapitonov, Ivana Grabundzija, Zoltan Ivics
-
Patent number: 11384071Abstract: Chemical compounds that are useful as inhibitors of mechanotransduction in the treatment of pain and modulation of touch perception and topical administration of the compounds described herein in the treatment of pain and modulation of touch perception.Type: GrantFiled: December 7, 2017Date of Patent: July 12, 2022Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventors: Gary Richard Lewin, Kathryn Anne Poole, Christiane Wetzel, Liudmila Lapatsina
-
Patent number: 11377636Abstract: An in vitro method for identifying, isolating and/or enriching primate naive pluripotent stem cells, the method including analyzing transcription of a type 7 long terminal repeat (LTR7) nucleic acid sequence of a type H human endogenous retrovirus (HERVH) (LTR7/HERVH-associated transcription), and identifying, isolating and/or enriching primate naive pluripotent stem cells based on LTR7/HERVH-associated transcription, wherein LTR7/HERVH-associated transcription is a marker for primate naive pluripotent stem cells. An isolated in vitro population of primate naive pluripotent stem cells is obtained by the method, wherein in the cells LTR7/HERVH-associated transcription is elevated in comparison to control cells, wherein control cells are primed pluripotent stem cells or differentiated cells.Type: GrantFiled: September 6, 2019Date of Patent: July 5, 2022Assignees: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, UNIVERSITY OF BATHInventors: Jichang Wang, Zsuzsanna Izsvák, Laurence Daniel Hurst
-
Publication number: 20220202872Abstract: A method for generating a three-dimensional neuromuscular organoid in vitro is disclosed.Type: ApplicationFiled: July 9, 2021Publication date: June 30, 2022Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventor: Asimina GKOUTI
-
Patent number: 11365183Abstract: The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.Type: GrantFiled: March 25, 2019Date of Patent: June 21, 2022Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, BOARD OF REGENTS OF UNIVERSITY OF TEXAS SYSTEMInventors: Wolf-Hagen Schunck, Gerd Wallukat, Robert Fischer, Cosima Arnold, Dominik N. Mueller, Narender Puli, John R. Falck
-
Patent number: 11337909Abstract: A cosmetic method for modulating pigmentation in a subject includes administering a modulator of angiotensin-converting enzyme 2 (ACE2 modulator) to the subject. The ACE2 modulator can be an inhibitor of angiotensin-converting enzyme 2 (ACE2 inhibitor), in which case, the ACE2 inhibitor can be administered to increase pigmentation in the subject. The ACE2 modulator can also be an activator of angiotensin-converting enzyme 2 (ACE2 activator), in which case the ACE2 activator can be administered to decrease pigmentation in the subject. The treatment of inflammatory skin disease can also be achieved by inhibition of angiotensin-converting enzyme 2.Type: GrantFiled: November 29, 2018Date of Patent: May 24, 2022Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventors: Michael Bader, Fatimunnisa Qadri, Mihail Todiras, Natalia Alenina
-
Patent number: 11331290Abstract: A method for inhibiting, reducing and/or reducing the risk of cancer metastasis in a subject, including identifying a subject as in need of inhibiting, reducing and/or reducing the risk of cancer metastasis, by identifying the subject as having a cancer with an elevated or up-regulated level of S100A4 transcription compared to a level in non-oncogenic cells, and administering to the subject a therapeutically effective amount of niclosamide or a niclosamide derivate, thereby inhibiting or reducing S100A4 transcription, so as to inhibit, reduce and/or reduce the risk of cancer metastasis, wherein 15 to 400 mg niclosamide or niclosamide derivate is administered per kg body weight of the subject (mg/kg), 1 or 2 times daily.Type: GrantFiled: January 28, 2020Date of Patent: May 17, 2022Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventors: Ulrike Stein, Wolfgang Walther, Ulrike Sack, Peter M. Schlag
-
Patent number: 11294163Abstract: A microscope-autofocus device for feedback-controlling a focal position of an imaging system of a microscope apparatus, wherein the imaging system includes a microscope objective, a monitoring beam source for creating a monitoring beam, a detector device for detecting a drift variation of an axial objective distance between the microscope objective and a sample by sensing the monitoring beam directed through the imaging system to the sample and reflected by the sample, and a feedback loop device for controlling the imaging system in dependency on the detected objective distance variation of the microscope objective.Type: GrantFiled: October 18, 2018Date of Patent: April 5, 2022Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventors: Paolo Annibale, Marc Bathe-Peters, Martin Lohse
-
Publication number: 20210302442Abstract: The present invention relates to a method for the quantification of seeding (?t50) of an amyloidogenic aggregate, methods for assessing the risk for development, predicting the onset or assessing the progression of a polyQ disease, and a method for identifying compounds that inhibit mHTT seeding activity (HSA) in vitro. Further, uses of fluorophore-bearing polyQ proteins, particularly mutant N-terminal huntingtin fragments comprising exon-1 and related soluble protein constructs are provided.Type: ApplicationFiled: August 7, 2019Publication date: September 30, 2021Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventors: Anne AST, Alexander BUNTRU, Erich WANKER
-
Patent number: 11028084Abstract: A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-?B kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-?B) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-?B activation.Type: GrantFiled: November 14, 2017Date of Patent: June 8, 2021Assignees: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, Forschungsverbund Berlin e.VInventors: Claus Scheidereit, Michael Willenbrock, Peter Lindemann, Silke Radetzki, Jens-Peter Von Kries, Marc Nazare